MAVENCLAD™ (cladribine tablets) │ EMD Serono
We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck KGaA, Darmstadt, Germany representative.
This page requires you to register for an account with Merck KGaA, Darmstadt, Germany.

{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}


Patients without relapse over 96 weeks (secondary endpoint)*

Relapse-Free Relapse-Free

At 96 weeks, 79.7% of patients were relapse-free with MAVENCLAD vs. 60.9% for placebo (p<0.001; OR: 2.53 [95% CI: 1.87-3.43])1,2  

Learn more about MAVENCLAD


Demonstrated reduction in ARR


Demonstrated reduction in 3-month EDSS progression

Demonstrated reduction in brain lesions



See how MAVENCLAD achieved
a 57.6% relative reduction in ARR over 96 weeks vs. placebo
(p<0.001, 0.14 vs. 0.33, respectively).   

Learn more

See how MAVENCLAD delivered a 33%
reduction in risk of disability progression (EDSS) vs. placebo (p=0.02, HR: 0.67,
secondary endpoint).

Learn more

Discover how MAVENCLAD
demonstrated an 86% relative
reduction in T1 Gd+ lesions and
73% in T2 lesions over 96 weeks
vs. placebo (p<0.001; mean lesions:
T1 Gd+, 0.12 vs. 0.91; T2,  0.38 vs. 1.43; secondary endpoint).  

Learn more

Footnotes and References

ARR=annualized relapse rate; EDSS=Expanded Disability Status Scale; Gd+=gadolinium-enhancing; OR=odds ratio

* 96-week, phase III, multicentre, double-blind, placebo-controlled trial to evaluate the safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis. 1,326 patients were randomized (1:1:1) to receive a cumulative dose of cladribine tablets (3.5 mg/kg [n=433] or 5.25 mg/kg [n=456]) or placebo (n=437), in two treatment courses. The 5.25 mg/kg dosage regimen is not available.1 

  1. MAVENCLAD™ Product Monograph. EMD Serono. November 2017.
  2. Giovannoni G, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26.

You are leaving our website

You are now leaving our website. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and make no representation to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third-party website does not constitute an endorsement by our company of such website or the information or products presented on such website.